Lung Cancer Screening in a Population Exposed to Occupational Lung Carcinogens (LUCSO)

February 8, 2023 updated by: Centre Hospitalier Intercommunal Creteil

LUng Cancer Screening With Low-dose Computed Tomography in a Population Exposed to Occupational Lung Carcinogens

The good clinical practice guidelines for the surveillance of workers after occupational exposure to lung carcinogens were approved by the Haute Autorité de la Santé (French National Authority for Health) and the Institut National du Cancer (French National Cancer Institute) in December 2015 and one recommendation of these guidelines concerns the setting-up of a trial of low-dose chest computed tomography (CT) lung cancer screening in subjects occupationally exposed to lung carcinogens at high-risk of lung cancer (Expert consensus).

In LUCSO study, the investigators propose to conduct, under strictly defined conditions, a feasibility study of lung cancer screening in a population defined as being at high risk of lung cancer according to these good clinical practice guidelines. This population consists of smokers, aged from 55 to 74 years, currently or previously exposed to International Agency for Research on Cancer lung group 1 lung carcinogens.

The primary objective of this study is to evaluate the complex organization of lung cancer screening in the target population. This evaluation will focus on the following indicators:

  • Screening activity indicator: screening coverage rate over two years
  • Test quality indicator: validity of self-administered questionnaires to target the high-risk population
  • Examination quality indicator: lung cancer detection rate, lung cancer detection rates by stage, validity of low-dose chest CT scan
  • Follow-up indicator: smoking cessation rate, mortality rate This trial will be conducted in 8 French departments, by six reference centers specialized in occupational health (SRC).

In view of the exploratory nature of this trial, it is proposed to initially test the feasibility and acceptability of lung cancer screening sequentially over the first two years (Phase 1: 2021-2023, 24 months) in only two SRC (Val-de-Marne and Gironde).

The trial will be conducted in several steps:

  1. Identification of subjects currently or previously occupationally exposed to lung carcinogens by a screening invitation letter sent by Departmental Cancer Screening Centers to subjects aged from 55 to 74 years.
  2. Evaluation of occupational exposure to lung carcinogens
  3. Evaluation of the lung cancer risk level and verification of eligibility
  4. Screening procedure: Chest CT scans will be performed by centers specialized in chest imaging
  5. Lung cancer follow-up when an abnormality suggestive of lung cancer is demonstrated.

Study Overview

Status

Recruiting

Conditions

Detailed Description

The good clinical practice guidelines for the surveillance of workers after occupational exposure to lung carcinogens were approved by the Haute Autorité de la Santé (French National Authority for Health) and the Institut National du Cancer (French National Cancer Institute) in December 2015 and the Recommendation R12 of these guidelines concerns the setting-up of a trial of low-dose chest computed tomography (CT) lung cancer screening in subjects occupationally exposed to lung carcinogens at high-risk of lung cancer (Expert consensus).

In LUCSO study, the investigators propose to conduct, under strictly defined conditions, a feasibility study of lung cancer screening in a population defined as being at high risk of lung cancer according to these good clinical practice guidelines. This population consists of smokers, aged from 55 to 74 years, currently or previously exposed to International Agency for Research on Cancer lung group 1 lung carcinogens.

The primary objective of this study is to evaluate the organization of lung cancer screening in the target population. This evaluation will focus on the following indicators:

  • Screening activity indicator: screening coverage rate over two years
  • Test quality indicator: validity of self-administered questionnaires to target the high-risk population
  • Examination quality indicator: lung cancer detection rate, lung cancer detection rates by stage, validity of low-dose chest CT scan
  • Follow-up indicator: smoking cessation rate, mortality rate

The secondary objectives of the study are:

  • Describe the population recruited in each step of the protocol
  • Develop a tool to identify subjects exposed to pulmonary carcinogens and with high-risk of lung cancer
  • Evaluate the impact of the proposed screening programme on smoking cessation at one, two and three years.
  • Evaluate the social impact of the screening campaign
  • Conduct a cost-effectiveness analysis of the programme

The proposed study will take place in multidisciplinary and specialized reference centers (SRC) in various French districts participating in the programme, to welcome patients participating. It is organized into six workpackages (WP):

  • WP1: Methodology - Epidemiology
  • WP2: Evaluation of occupational exposure
  • WP3: Imaging
  • WP4: Lung cancer follow-up strategy
  • WP5: Smoking cessation
  • WP6: Medico-economic analysis Six specialized reference centers are proposed in four different regions in order to test a potential region effect and to allow the recruitment by each SRC of about 200 to 600 new eligible subjects per year and per department according to the population and the age pyramid of each department
  • SRC1: Centre Intercommunal de Créteil for the Val-de-Marne (94), Seine-et-Marne (77), and Essonne (91) departments
  • SRC2: Bordeaux University Hospital for the Gironde (33) department
  • SRC3: Rennes University Hospital for the Ille-et-Vilaine (35) department
  • SRC4: Brest University Hospital for the Finistère (29) department
  • SRC5: Caen University Hospital for the Calvados (14) department
  • SRC6: Rouen University Hospital for the Seine-Maritime (76) department

Each of these centers is voluntary and possesses the four essential prerequisites: an occupational health clinic - radiology team with specific skills in chest imaging - pulmonology team or network of pulmonologists specialized in lung cancer - smoking cessation team.

In view of the complexity of this organization, it is proposed to initially test the feasibility and acceptability of the screening programme sequentially for the first two years (24 months) in two SRCs (SRC1 and SRC2): "Phase 1: 2021-2023". It is expected to extend the study to the other SRCs after two years: "Phase 2: 2023-2029". Ad hoc adjustments will be decided for the creation of SRCs in the third year on the basis of the data acquired in the two pilot departments, especially on the expected target population participation rate. Mortality will be monitored at least until 2031.

The trial will be conducted in several steps:

  1. Identification of subjects currently or previously occupationally exposed to lung carcinogens by a screening invitation letter sent by Departmental Cancer Screening Centers to subjects aged from 55 to 74 years.
  2. Evaluation of occupational exposure to lung carcinogens
  3. Evaluation of the lung cancer risk level and verification of eligibility
  4. Screening procedure: Chest CT scans will be performed by centers specialized in chest imaging
  5. Lung cancer follow-up when an abnormality suggestive of lung cancer is demonstrated.

Study Type

Observational

Enrollment (Anticipated)

6000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bordeaux, France, 33076
        • Recruiting
        • Centre Hospitalier Universitaire de Bordeaux
      • Bordeaux, France, 33076
        • Active, not recruiting
        • Universite de Bordeaux
      • Brest, France, 29609
        • Not yet recruiting
        • Centre Hospitalier Universitaire de Brest
        • Contact:
          • David LUCAS, Dr
      • Caen, France, 14033
        • Not yet recruiting
        • Centre Hospitalier Universitaire de Caen
      • Créteil, France, 94010
        • Recruiting
        • Centre Hospitalier Intercommunal de Créteil
      • Rennes, France, 35033
        • Not yet recruiting
        • Centre Hospitalier Universitaire de Rennes
      • Rouen, France, 76032
        • Not yet recruiting
        • Centre Hospitalier Universitaire de Rouen
      • Toulon, France, 83000
        • Not yet recruiting
        • Hôpital d'Instruction des Armées Sainte-Anne

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

55 years to 74 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Subjects aged from 55 to 74 years, current smokers smoking 30 pack-years or more or ex-smokers smoking 30 pack-years or more and who have quit smoking for less than 15 years and currently or previously occupationally exposed to lung carcinogens. These subjects are known to be high-risk population for lung cancer.

Description

Inclusion Criteria:

Subjects at high risk of lung cancer: current smokers smoking 30 pack-years or more or ex-smokers smoking 30 pack-years or more and who have quit smoking for less than 15 years and currently or previously occupationally exposed to lung carcinogens. With an algorithm for determination of minimal duration of exposure to occupational carcinogens (according to the type and duration of occupational lung carcinogens)

Exclusion Criteria:

  • Presence of clinical signs of lung cancer
  • Subjects with a history of lung cancer
  • Presence of serious short-term life-threatening comorbidities
  • Absence of occupational exposure to lung carcinogens according to the predefined criteria
  • Subjects already included in another prospective cohort study
  • Subjects already assessed by chest CT scan during the previous year
  • No tobacco exposure or insufficient tobacco exposure or smoking cessation for more than 15 years.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of detected lung cancer
Time Frame: Year 1
The proportion of subjects with lung cancer detected among the subjects performing the low-dose chest CT scan
Year 1

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of detected lung cancer
Time Frame: Year 2
The proportion of subjects with lung cancer detected among the subjects performing the low-dose chest CT scan
Year 2
Rate of detected lung cancer
Time Frame: Day 0
The proportion of subjects with lung cancer detected among the subjects performing the low-dose chest CT scan
Day 0
Participation rate
Time Frame: Day 0
The proportion of subjects performing the low-dose chest CT scan among eligible responders during the first phase of the study
Day 0
Rate of detected lung cancer in subjects exposed to occupational carcinogens
Time Frame: Day 0
The proportion of subjects with lung cancer detected among the subjects exposed to occupational carcinogens and performing the low-dose chest CT scan
Day 0
Rate of detected lung cancer in subjects exposed to occupational carcinogens
Time Frame: Year 1
The proportion of subjects with lung cancer detected among the subjects exposed to occupational carcinogens and performing the low-dose chest CT scan
Year 1
Rate of detected lung cancer in subjects exposed to occupational carcinogens
Time Frame: Year 2
The proportion of subjects with lung cancer detected among the subjects exposed to occupational carcinogens and performing the low-dose chest CT scan
Year 2
Stage of detected lung cancers
Time Frame: Day 0
Day 0
Stage of detected lung cancers
Time Frame: Year 1
Year 1
Stage of detected lung cancers
Time Frame: Year 2
Year 2
Smoking cessation rate obtained in smokers in the sreened population
Time Frame: Year 3
The proportion of subjects with smoking cessation among smokers
Year 3
Mortality rate in the sreened population
Time Frame: Year 3
Year 3
Mortality rate in the sreened population
Time Frame: Year 5
Year 5
Mortality rate in the sreened population
Time Frame: Year 7
Year 7
Mortality rate in the non-screened population
Time Frame: Year 3
Year 3
Mortality rate in the non-screened population
Time Frame: Year 5
Year 5
Lung cancer rate in non-screened subjects but met at the Occupational Disease Consultation Center
Time Frame: Year 3
Year 3
Mortality rate in the non-screened population
Time Frame: Year 7
Year 7
Lung cancer rate in non-screened subjects but met at the Occupational Disease Consultation Center
Time Frame: Year 5
Year 5
Lung cancer rate in non-screened subjects but met at the Occupational Disease Consultation Center
Time Frame: Year 7
Year 7
Rate of detected lung cancer and stage of detected lung cancer in the non-screened population
Time Frame: Year 3
Year 3
Rate of detected lung cancer and stage of detected lung cancer in the non-screened population
Time Frame: Year 5
Year 5
Rate of detected lung cancer and stage of detected lung cancer in the non-screened population
Time Frame: Year 7
Year 7
Percentage of subjects participating in all screening (over the three years)
Time Frame: Year 3
Year 3
Percentage of subjects participating in all screening (over the three years)
Time Frame: Year 4
Year 4
Percentage of the subjects lost during follow-up in the screened population (follow-up at one year, two years, completion of other complementary exams)
Time Frame: Year 1
Year 1
Percentage of the subjects lost during follow-up in the screened population (follow-up at one year, two years, completion of other complementary exams)
Time Frame: Year 2
Year 2
Validity of the detailed personalised self-administered questionnaire for the evaluation of occupational exposures
Time Frame: Day 0
Day 0
Number of cases recognized as occupational disease (for lung cancer or other occupational diseases)
Time Frame: Year 2
Year 2
Proportion of invasive diagnostic procedures
Time Frame: Day 0
Day 0
Proportion of invasive diagnostic procedures
Time Frame: Year 1
Year 1
Proportion of invasive diagnostic procedures
Time Frame: Year 2
Year 2
Proportion of non-invasive diagnostic procedures
Time Frame: Day 0
Day 0
Proportion of non-invasive diagnostic procedures
Time Frame: Year 1
Year 1
Proportion of non-invasive diagnostic procedures
Time Frame: Year 2
Year 2
Proportion of serious and non-serious adverse events related to screening
Time Frame: Day 0
Day 0
Proportion of serious and non-serious adverse events related to screening
Time Frame: Year 1
Year 1
Proportion of serious and non-serious adverse events related to screening
Time Frame: Year 2
Year 2
Proportion of subjects stopping smoking at each stage of screening
Time Frame: Day 0
Day 0
Proportion of subjects stopping smoking at each stage of screening
Time Frame: Year 1
Year 1
Proportion of subjects stopping smoking at each stage of screening
Time Frame: Year 2
Year 2
The time period between each step of the screening (evaluation of the exposure, addressing in consultation of occupational diseases, inclusion, different exams of the follow-up)
Time Frame: Day 0
Day 0
The time period between each step of the screening (evaluation of the exposure, addressing in consultation of occupational diseases, inclusion, different exams of the follow-up)
Time Frame: Year 1
Year 1
The time period between each step of the screening (evaluation of the exposure, addressing in consultation of occupational diseases, inclusion, different exams of the follow-up)
Time Frame: Year 3
Year 3
Number of additional radiological examinations performed besides the prescribed CT scans of the protocol
Time Frame: Subject inclusion
Subject inclusion
Number of additional radiological examinations performed besides the prescribed CT scans of the protocol
Time Frame: Year 1
Year 1
Number of additional radiological examinations performed besides the prescribed CT scans of the protocol
Time Frame: Year 2
Year 2
Number of additional radiological examinations performed besides the prescribed CT scans of the protocol
Time Frame: Year 3
Year 3
Number of additional radiological examinations performed besides the prescribed CT scans of the protocol
Time Frame: Year 4
Year 4
Number of additional radiological examinations performed besides the prescribed CT scans of the protocol
Time Frame: Year 5
Year 5
Number of hospitalizations
Time Frame: Subject inclusion
Subject inclusion
Number of hospitalizations
Time Frame: Year 1
Year 1
Number of hospitalizations
Time Frame: Year 2
Year 2
Number of hospitalizations
Time Frame: Year 3
Year 3
Number of hospitalizations
Time Frame: Year 4
Year 4
Number of hospitalizations
Time Frame: Year 5
Year 5
Number of lung surgery
Time Frame: Subject inclusion
Subject inclusion
Number of lung surgery
Time Frame: Year 1
Year 1
Number of lung surgery
Time Frame: Year 2
Year 2
Number of lung surgery
Time Frame: Year 3
Year 3
Number of lung surgery
Time Frame: Year 4
Year 4
Number of lung surgery
Time Frame: Year 5
Year 5
Number of chemotherapy
Time Frame: Day 0
Day 0
Number of chemotherapy
Time Frame: Year 1
Year 1
Number of chemotherapy
Time Frame: Year 2
Year 2
Number of chemotherapy
Time Frame: Year 3
Year 3
Number of chemotherapy
Time Frame: Year 4
Year 4
Number of chemotherapy
Time Frame: Year 5
Year 5

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

July 22, 2021

Primary Completion (ANTICIPATED)

July 1, 2026

Study Completion (ANTICIPATED)

July 31, 2031

Study Registration Dates

First Submitted

April 16, 2018

First Submitted That Met QC Criteria

June 18, 2018

First Posted (ACTUAL)

June 19, 2018

Study Record Updates

Last Update Posted (ESTIMATE)

February 9, 2023

Last Update Submitted That Met QC Criteria

February 8, 2023

Last Verified

February 1, 2023

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lung Cancer

3
Subscribe